Navigation Links
Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
Date:5/7/2009

certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs. The Company's forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza's business are described in additional detail in the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and the Company's other Periodic and Current Reports filed with the Securities and Exchange Commission including the risks under the headings "We have a history of net losses. We expect to continue to incur substantial and increasing net losses for the foreseeable future, and we may never achieve or maintain profitability.", "We will need substantial additional capital in the future. If additional capital is not available, we will have to delay, reduce or cease operations.", "Failure or delay in commencing or completing clinical trials for our product candidates could harm our business.", and "Regulatory authorities may not approve our product candidates even if they meet safety and efficacy endpoints in clinical trials." Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

                           Alexza Pharmaceuticals, Inc.
                          (a development stage company)
                  Condensed Consolidated Statements of Operations
                   (unaudited, in thousands except per share data)

                                                    Three Months Ended
                                                          March 31,
                                                   2009              2008
    Revenue                 
'/>"/>
SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
2. Alexza Initiates AZ-104 (Staccato(R) Loxapine) Phase 2b Clinical Trial in Patients With Migraine Headaches
3. Alexzas AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
4. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
5. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
6. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
7. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
8. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
9. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
10. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
11. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 Torrance Memorial Medical Center ... ventilator technology from Covidien to provide a simple, ... The acute care ventilator is designed ... conventional mechanical ventilation, and help clinicians move patients ... on mechanical ventilation are often sedated to ease ...
(Date:8/20/2014)... 20, 2014 Children aren,t the only ... to help prevent disease. The Centers for Disease ... adults, but currently, many adults are not following ... Immunization Awareness Month, and the American Lung Association ... those with lung disease, to talk with their ...
(Date:8/20/2014)... 20, 2014 Research and Markets  has announced ... report to their offering. Global Market ... on Pralmorelin globally and regionally ( Europe , ... , Latin America etc.). It captures ... This report focuses on three primary areas; manufacture methods & ...
Breaking Medicine Technology:Torrance Memorial Medical Center Acquires Advanced Ventilator Technology to Enhance Patient Care 2American Lung Association Urges Adults with Lung Disease to Consult their Health Care Provider to Stay Current on Vaccinations 2American Lung Association Urges Adults with Lung Disease to Consult their Health Care Provider to Stay Current on Vaccinations 3Global Market Report of Pralmorelin 2
... for Safe Biologic Medicines will have an open ... on biologic medicines and pharmacovigilance.  Dr. Richard Dolinar, a practicing ... newly released FDA draft guidances for manufacturers of ... it and why is it important?  will ...
... MusculoskeletalNetwork , an online resource for ... now features a summary of the key orthopedic findings ... Academy of Orthopaedic Surgeons ( AAOS ) this February ... offers orthopedists a comprehensive program with the latest in ...
Cached Medicine Technology:Alliance for Safe Biologic Medicines Announces New Webinar on February 16 2UBM Medica's Musculoskeletal Network Highlights Key Orthopedic Findings From AAOS 2UBM Medica's Musculoskeletal Network Highlights Key Orthopedic Findings From AAOS 3
(Date:8/20/2014)... The Board of Directors of top international ... pleased to announce the expansion of its healthcare ... and the surrounding region. In support of this strategic ... has relocated to the firm’s office in Shanghai, China, ... design and to better support regional clients. , ...
(Date:8/20/2014)... persistent and deadliest infectious diseases in the world, killing ... who study tuberculosis have long debated its origins. New ... Africa to seals and sea lions that brought the ... people there before Europeans landed on the continent. , ... Source of New World Human Tuberculosis," was published in ...
(Date:8/20/2014)... to spawning grounds through fast-moving waters may be at ... scientists. , When salmon encounter turbulent, fast-moving water ... they must move upstream using a behaviour known as ... , "Days after sockeye passed through extremely fast-moving water, ... distance from their spawning grounds," said Nicholas Burnett, a ...
(Date:8/20/2014)... New York (PRWEB) August 20, 2014 ... the use of power morcellators ( http://www.injurybeacon.com/power-morcellator/ ) ... notes that two U.S. Senators from New York are ... seek a recall of the devices. In a letter ... both Democrats, also implored the agency to seriously consider ...
(Date:8/20/2014)... NEW YORK, NY (August 20, 2014) Research from ... a critical role in stomach cancer growth and that ... be an effective treatment for the disease. The study ... MD, in collaboration with Duan Chen, MD, PhD, in ... Science Translational Medicine . , "Scientists have long observed ...
Breaking Medicine News(10 mins):Health News:Perkins Eastman Expands Presence in China 2Health News:Perkins Eastman Expands Presence in China 3Health News:New research shows seals and sea lions likely spread tuberculosis to humans 2Health News:New research shows seals and sea lions likely spread tuberculosis to humans 3Health News:Salmon forced to 'sprint' less likely to survive migration 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 4Health News:Severing nerves may shrink stomach cancers: Botox injections slow growth of tumors in mice 2
... Conn.Yale School of Medicine is hosting a two-day symposium Nov. ... the late actor John Ritter, who died of an aortic ... Diseases: Lux et Veritas will be held in Mary S. ... program is John Elefteriades, M.D., section chief of cardiothoracic surgery ...
... the United States via Haiti, probably arriving in just one ... new research. , After the virus, HIV-1, entered the ... results show that the strain of virus that spawned the ... is earlier than a lot of people had imagined," said ...
... and Asia are born and die without leaving a ... little information on which to base public health decisions, ... and colleagues say in a paper published today (Oct. ... , However, affordable solutions exist to collect these vital ...
... study finds it can prevent or shorten the illness , ... in the blood may help prevent pneumonia in elderly nursing ... at Tufts University looked at 617 people 65 and older ... found that those with normal blood zinc concentrations were about ...
... National Campaign to Inspire and ... Educate that Prevention is Possible, BERKELEY, Calif., Oct. 29 ... lifetime. Although 50 percent,of women think breast cancer is hereditary, only ... disease. LUNA, the makers of whole nutrition bars for women(R), ...
... patients with Philadelphia, chromosome-positive chronic myeloid leukemia resistant or intolerant to ... ... Novartis can offer physicians and patients a ... Tasigna(R),(nilotinib) capsules have been approved in the US as a new ...
Cached Medicine News:Health News:HIV's path out of Africa: Haiti, the US then the world 2Health News:HIV's path out of Africa: Haiti, the US then the world 3Health News:Scandal of invisibility plagues countries with no civil registries 2Health News:Scandal of invisibility plagues countries with no civil registries 3Health News:Zinc Helps Elderly Ward Off Pneumonia 2Health News:LUNA Pure Prevention Survey Confirms Breast Cancer Misconceptions 2Health News:LUNA Pure Prevention Survey Confirms Breast Cancer Misconceptions 3Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 2Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 3Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 4Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 5Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 6Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 7Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 8Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 9Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 10
The latex free, hydrophilic Self-Cath Plus is designed for single use, intermittent self-catheterization. The unique hydrophilic coating activates immediately upon exposure to water for fast, clean...
... The Self-Cath Closed System is a ... method for safe, simple catheterization designed ... tract infections. It includes a ... The new EasyOff tear tab makes ...
... Self-Cath family of 100% ... a variety of options ... Each catheter is made ... PVC and has smooth ...
... The Self-Cath family ... offers patients a variety ... self-catheterization. Each catheter ... medical grade PVC and ...
Medicine Products: